1832 Asset Management’s Standard BioTools LAB Stock Holding History

1832 Asset Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-63,482	Closed	-$1.87M	–	636
2014 Q2	$1.87M	Buy	63,482 +6,800	+12%	+$218K	0.01%	428
2014 Q1	$2.4M	Sell	56,682 -2,900	-5%	-$128K	0.01%	410
2013 Q4	$2.29M	Buy	59,582 +43,782	+277%	+$1.29M	0.01%	358
2013 Q3	$346K	Sell	15,800 -14,200	-47%	-$279K	﹤0.01%	361
2013 Q2	$524K	Buy	+30,000	New	+$526K	﹤0.01%	368

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

1832 Asset Management's LAB Position: Q3 2014 in Review

1832 Asset Management sold out of Standard BioTools (LAB) in Q3 2014, closing a stake of 63,482 shares — an estimated $1.87M sold.

1832 Asset Management first reported a position in LAB in Q2 2013 and held it in 5 quarters. The position peaked at $2.4M in Q1 2014. 99 funds tracked by Wall St. Rank hold LAB as of Q3 2014.

1832 Asset Management reported no remaining Standard BioTools position as of Q3 2014 after selling out during the quarter.
1832 Asset Management sold 63,482 Standard BioTools shares in Q3 2014, an estimated $1.87M.
1832 Asset Management first reported a position in Standard BioTools in Q2 2013 and held it in 5 quarters.
1832 Asset Management's Standard BioTools position peaked at $2.4M in Q1 2014.
99 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2014.

Based on 1832 Asset Management's 13F filing for Q3 2014, filed 12 Nov 2014.